Early treatment with JNJ-46356479, a mGluR2 modulator, improves behavioral and neuropathological deficits in a postnatal ketamine mouse model of schizophrenia.
Saved in:
| Title: | Early treatment with JNJ-46356479, a mGluR2 modulator, improves behavioral and neuropathological deficits in a postnatal ketamine mouse model of schizophrenia. |
|---|---|
| Authors: | Martínez-Pinteño, A.1 (AUTHOR), Rodríguez, N.1,2 (AUTHOR), Olivares, D.1 (AUTHOR), Madero, S.3 (AUTHOR), Gómez, M.3,4 (AUTHOR), Prohens, L.1 (AUTHOR), García-Rizo, C.2,3,4 (AUTHOR), Mas, S.1,2,4 (AUTHOR), Morén, C.2,3,5 (AUTHOR), Parellada, E.1,2,3,4 (AUTHOR) eparella@clinic.cat, Gassó, P.1,2,4 (AUTHOR) pgasso@ub.edu |
| Source: | Biomedicine & Pharmacotherapy. Feb2023, Vol. 158, pN.PAG-N.PAG. 1p. |
| Database: | Academic Search Ultimate |
| ISSN: | 07533322 |
|---|---|
| DOI: | 10.1016/j.biopha.2022.114079 |
